Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval

Oral CGRP Inhibitor Is First For Dual Use

CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.

Woman with severe migraine headache
Nurtec was approved for acute treatment of migraine before it was cleared for migraine prevention • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd. will go head-to-head with even more big pharma competitors now that its oral CGRP inhibitor Nurtec ODT (rimegepant) is approved for migraine prevention, making it the first drug available in the US to stop migraine headaches when they happen and to prevent them from occurring in the first place. CEO Vlad Coric told Scrip that the customizable use of Nurtec is a major differentiator in the eyes of patients and physicians, and said it appeals to payers as well.

The US Food and Drug Administration approved Nurtec in early 2020 as an acute treatment – an on-demand therapy to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip